Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

More coming I am sure. They'll continue to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jfk Member Profile
 
Followed By 2
Posts 300
Boards Moderated 0
Alias Born 05/10/07
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/1/2020 4:53:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2020 4:16:53 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/25/2020 4:15:36 PM
Brainstorm Announces Grant of a New Japanese Patent for NurOwn® PR Newswire (US) - 9/16/2020 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2020 4:08:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:06:53 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/10/2020 6:07:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 7:01:27 AM
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update PR Newswire (US) - 8/5/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 5:11:22 PM
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update PR Newswire (US) - 7/27/2020 7:58:00 AM
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:16:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:10:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:05:43 PM
BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program PR Newswire (US) - 7/8/2020 5:31:00 AM
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS PR Newswire (US) - 7/2/2020 6:49:00 AM
BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar PR Newswire (US) - 7/1/2020 8:50:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/26/2020 5:02:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/26/2020 5:01:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/26/2020 5:01:04 PM
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease PR Newswire (US) - 6/24/2020 7:00:00 AM
BrainStorm Granted SME Status by the European Medicines Agency GlobeNewswire Inc. - 6/15/2020 9:00:10 AM
BrainStorm to Present at the Raymond James Human Health Innovations Conference PR Newswire (US) - 6/11/2020 7:28:00 AM
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study PR Newswire (US) - 6/9/2020 6:00:00 AM
jfk   Thursday, 07/23/20 01:57:01 PM
Re: JohnCM post# 2746
Post # of 2817 
More coming I am sure. They'll continue to throw new irons on the fire. All their new hires are now, or soon to be, earning their positions. Dr. Kern is prefect for this company, and Chaim is continuing to crack his whip.
$35 by Q1. Will we ever get an opportunity to re-enter cheaper than this? The significant insider buys at $13 was the biggest tell of all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences